(2021) Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis. Frontiers in Microbiology. p. 13.
Full text not available from this repository.
Abstract
Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis (MTB) remain a primary global threat to the end of tuberculosis (TB) era. Delamanid (DLM) is a nitro-dihydro-imidazooxazole derivative utilized to treat MDR-TB. DLM has distinct mechanism of action, inhibiting methoxy- and keto-mycolic acid (MA) synthesis through the F420 coenzyme mycobacteria system and generating nitrous oxide. While DLM resistance among MTB strains is uncommon, there are increasing reports in Asia and Europe, and such resistance will prolong the treatment courses of patients infected with MDR-TB. In this review, we address the antimycobacterial properties of DLM, report the global prevalence of DLM resistance, discuss the synergism of DLM with other anti-TB drugs, and evaluate the documented clinical trials to provide new insights into the clinical use of this antibiotic.</p>
| Item Type: | Article | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creators: |
|
||||||||||||||||||||
| Keywords: | Mycobacterium tuberculosis tuberculosis delamanid review TB additional drug-resistance antituberculosis drugs bactericidal activity bedaquiline opc-67683 therapy tb compassionate adolescents prevalence Microbiology | ||||||||||||||||||||
| Divisions: | |||||||||||||||||||||
| Page Range: | p. 13 | ||||||||||||||||||||
| Journal or Publication Title: | Frontiers in Microbiology | ||||||||||||||||||||
| Journal Index: | ISI | ||||||||||||||||||||
| Volume: | 12 | ||||||||||||||||||||
| Identification Number: | https://doi.org/10.3389/fmicb.2021.717045 | ||||||||||||||||||||
| Depositing User: | مهندس مهدی شریفی | ||||||||||||||||||||
| URI: | http://eprints.medilam.ac.ir/id/eprint/3744 |
Actions (login required)
 |
View Item |